Parkinson disease
Neurology · 2008–2025
12decisions
8medicines
3carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| apomorphine Treatment of Parkinson disease in patients with severely disabling motor fluctuations refractory to conventional therapy. Maintenance therapy in patients who… | Jul 2025 | Recommended with restriction | input received |
| levodopa with carbidopa and entacapone Advanced idiopathic Parkinson disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Mar 2024 | Not recommended | 1 individuals |
| opicapone Adjunctive therapy to levodopa-decarboxylase inhibitor combination in adult patients with Parkinson disease experiencing end-of-dose motor fluctuations. | Jul 2021 | Recommended with restriction | input received |
| apomorphine Treatment of Parkinson disease in patients with severely disabling motor fluctuations not responding to other therapy, for maintenance therapy following… | Mar 2020 | Recommended with restriction | none received |
| apomorphine Treatment of Parkinson disease in patients with severely disabling motor fluctuations which have not responded to other therapy. | Nov 2016 | Recommended | none received |
| apomorphine hydrochloride Management of advanced Parkinson disease in patients with severely disabling motor fluctuations that have not responded to other therapy. | Nov 2014 | Recommended with restriction | no section in document |
| rasagiline Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor… | Mar 2012 | Recommended with restriction | unclear |
| rasagiline Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor… | Mar 2012 | Recommended with restriction | unclear |
| levodopa with carbidopa management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy; maintenance therapy… | Nov 2010 | Recommended with restriction | no section in document |
| pramipexole hydrochloride monotherapy for idiopathic Parkinson disease in patients with motor disability and no evidence of cognitive impairment | Jul 2009 | Recommended with restriction | no section in document |
| levodopa with carbidopa monohydrate, intestinal gel initial treatment commenced in a hospital based Movement Disorder Clinic for patients with advanced Parkinson disease with severe disabling motor fluctuations… | Mar 2009 | Not recommended | no section in document |
| pramipexole hydrochloride treatment of signs and symptoms of idiopathic Parkinson disease in advanced states of the disease (in combination with levodopa-decarboxylase inhibitor… | Jul 2008 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.